Easmon C S, Crane J P, Blowers A
J Antimicrob Chemother. 1986 Nov;18 Suppl D:43-8. doi: 10.1093/jac/18.supplement_d.43.
Ciprofloxacin is taken up rapidly by both human neutrophils and mouse peritoneal macrophages. It does not appear to be bound firmly within the cell and can be eluted readily if the extracellular concentration is lowered. Uptake does not depend on an active transport mechanism. Intracellular ciprofloxacin is biologically active reducing the survival of intracellular Staphylococcus aureus and Mycobacterium fortuitum, in vitro. In vivo, ciprofloxacin was effective in treating a murine systemic infection with an intracellular pathogen Salmonella typhimurium. The progress of infection in sensitive mice with no natural immunity was delayed by ciprofloxacin although at the dosage used the mice were not cured. These results suggested that clinical studies in patients infected by intracellular pathogens are warranted and that ciprofloxacin may have an important role in the treatment of this type of infection.
环丙沙星可被人类中性粒细胞和小鼠腹腔巨噬细胞迅速摄取。它似乎并未牢固地结合在细胞内，如果细胞外浓度降低，它可以很容易地被洗脱出来。摄取不依赖于主动转运机制。细胞内环丙沙星具有生物活性，在体外可降低细胞内金黄色葡萄球菌和偶然分枝杆菌的存活率。在体内，环丙沙星对治疗小鼠因细胞内病原体鼠伤寒沙门氏菌引起的全身感染有效。环丙沙星延缓了无天然免疫力的敏感小鼠感染的进展，尽管使用该剂量未能治愈小鼠。这些结果表明，对细胞内病原体感染患者进行临床研究是有必要的，并且环丙沙星在这类感染的治疗中可能发挥重要作用。
